























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































027	 31(19.0) 0.17(‐0.06‐3.94) 3.8x104(2.0x101	‐5.5x106)
014‐020	 26(16.0) 0.00(‐0.01‐0.51) 3.0x103(6.0x101‐4.0x105)
002	 9(5.5) 0.01	(‐0.05‐0.90) 4.0x104	(2.0x101–9.4x105)
053‐163	 8(4.9) 0.02(‐0.00‐2.33) 6.2x104(3.5x102‐2.2x106)
078‐126	 5(3.1) 0.32(‐0.02‐0.96) 7.5x104(7.5x101‐1.3x105)
015	 5(3.1) 0.00(‐0.01‐0.06) 2.6x104	(1.5x102‐1.5x104)
012	 2(1.2) 0.01(0.00‐0.01) 1.8x105(3.8x104‐3.8x105)
001	 1(0.6) 0.01(‐) 1.5x104(‐)	
003	 1(0.6) 1.48(‐) 8.1x105(‐)	
017	 1(0.6) 0.00(‐) 3.5x103(‐)	
Others*	 74(45.4) 0.01(‐0.06‐1.96) 3.3x104	(5.0x100‐2.3x106)










































































































































































































027	 31 0.17(‐0.06‐3.94) 6.2x104(3.5x102‐2.2x106)
014‐020	 26 0.00(‐0.01‐0.51) 3.0x103(6.0x101‐4.0x105)
002	 9 0.01	(‐0.05‐0.90) 4.0x104	(2.0x101–9.4x105)
SJ485	 9 0.10(‐0.00‐0.83) 1.9x104(9.9x102‐4.2x105)
053‐163	 8 0.02(‐0.00‐2.33) 6.2x104(3.5x102‐2.2x106)
SJ420	 7 0.28(‐0.00‐1.35) 1.3x105(7.5x102‐1.4x106)
SJ308	 6 0.00(‐0.00‐0.29) 6.8x104(7.5x101‐2.2x106)
SJ467	 6 1.16(‐0.00‐1.58) 3.3x105(1.4x104‐2.3x106)
078‐126	 5 0.32(‐0.02‐0.96) 7.5x104(7.5x101‐1.3x105)
015	 5 0.00(‐0.01‐0.06) 2.6x104	(1.5x102‐1.5x104)
SJ311	 5 0.41(‐0.01‐1.96) 3.5x104(3.0x103‐2.6x106)
SJ406	 4 0.09(‐0.01‐1.15) 1.1x105(1.2x103‐8.5x105)
SJ435	 4 ‐0.01(‐0.04‐0.01) 1.2x104(1.5x102‐4.2x104)
SJ312	 3 0.00(‐0.06‐0.01) 8.5x103(3.5x101‐1.5x106)
SJ402	 3 0.62(0.00‐0.91) 2.5x104(2.0x103‐6.9x104)
SJ423	 3 0.00(‐0.00‐1.35) 4.3x104(6.0x103‐6.0x104)
012	 2 0.01(0.00‐0.01) 1.8x105(3.8x104‐3.8x105)
SJ310	 2 0.00(0.00‐0.00) 1.2x104(1.8x103‐2.2x104)
SJ409	 2 0.14(0.01‐0.27) 3.1x103(1.5x102‐6.0x103)
SJ413	 2 0.93(‐0.00‐1.86) 1.1x104(4.5x103‐2.2x105)
SJ428	 2 0.00(0.00‐0.00) 1.5x104(1.5x102‐4.2x104)
SJ443	 2 0.58(0.00‐1.15) 6.5x104(1.5x104‐1.2x105)
SJ451	 2 1.41(1.24‐1.58) 1.4x105(6.0x104‐2.2x105)
001	 1 0.01(‐) 1.5x104(‐)
003	 1 1.48(‐) 8.1x105(‐)
017	 1 0.00(‐) 3.5x103(‐)
SJ313	 1 0.00(‐) 3.1x104(‐)
SJ316	 1 0.00(‐) 5.0x103(‐)
SJ318	 1 1.59(‐) 2.6x105(‐)
SJ405	 1 0.12(‐) 3.6x105(‐)
SJ407	 1 0.00(‐) 5.1x103(‐)
SJ412	 1 0.02(‐) 1.2x105(‐)
SJ442	 1 1.82(‐) 1.6x104(‐)
SJ448	 1 0.00(‐) 2.5x102(‐)
SJ459	 1 0.01(‐) 5.0x100(‐)
SJ464	 1 0.00(‐) 1.5x102(‐)
SJ468	 1 0.02(‐) 3.8x104(‐)
SJ494	 1 0.80(‐) 1.0x104(‐)




















































































































































































































































































































































































































































































Antibiotic	history		 	 101(84.17) 72(79.12) 0.34	 1.40	 0.69‐2.84
			Penicillins	 	 23(19.17) 28(30.77) 0.05	 0.53	 0.28‐1.01
			Cephalosporins	 	 81(67.50) 62(68.13) 0.92	 0.97	 0.54‐1.74
			Carbapenems	 	 5(4.17) 9(9.89) 0.10	 0.40	 0.13‐1.23
			Macrolides	 	 21(17.50) 9(9.89) 0.12	 1.93	 0.84‐4.45
			Quinolones	 	 23(19.17) 19(20.88) 0.75	 0.90	 0.46‐1.77
			Sulfonamides	 	 7(5.83) 4(4.40) 0.64	 1.35	 0.38‐4.75
			Tetracyclines	 	 1(0.83) 0(0) 0.38	 	
			Aminoglycosides	 	 5(4.17) 4(4.40) 0.94	 0.95	 0.25‐3.63
			Lincosamides	 	 18(15.00) 9(9.89) 0.27	 1.61	 0.69‐3.77
			Glycopeptides	 	 62(51.67) 41(45.05) 0.34	 1.30	 0.76‐2.25
			Amebicides	 	 45(37.50) 36(39.56) 0.76	 0.92	 0.52‐1.60
H2	blockers		 	 49(40.83) 28(30.77) 0.13	 1.55	 0.87‐2.76
Proton	pump	inhibitor		 	 57(47.50) 49(53.85) 0.36	 0.78	 0.45‐1.34
Corticosteroids		 	 40(33.33) 30(32.97) 0.96	 1.02	 0.57‐1.81
Chemotherapy	 	 9(7.50) 5(5.49) 0.56	 1.40	 0.45‐4.31
Previous	
hospitalization	
	 78(65.00) 52(57.14) 0.25	 1.39	 0.80‐2.44
Previous	surgery	 	 43(35.83) 24(26.37) 0.14	 1.56	 0.86‐2.83
Previous	CDI	episode	 	 17(14.17) 10(10.99) 0.49	 1.34	 0.58‐3.08
Use	of	laxatives	
(Previous	week)	










	 3.52(4.67) 2,83(6.32) 0.70	 1.02	 0.97‐1.08
CDI	severity	
		 76
WBC	(thou/mcL)	 	 13.48(7.76) 11.81(8.57) 0.02	 1.03	 0.99‐1.07
Creatinine	(mg/dL)	 	 1.42(1.19) 1.92(2.36) 0.84	 0.85	 0.72‐1.00
30‐days	Mortality	risk	 	 2.42(1.09) 2.72(1.18) 0.06	 0.79	 0.62‐1.00
Charlson	Comorbidity	
Score		
2	 2.17(1.53) 1.91(1.42) 0.19	 1.13	 0.93‐1.36
CDI	severity	 	 	
			Mild	 	 25(20.83) 24(26.37) 0.34	 0.74	 0.39‐1.40
			Moderate	 	 38(31.67) 33(36.26) 0.48	 0.81	 0.46‐1.45
			Severe	 	 46(38.33) 32(32.97) 0.42	 1.26	 0.71‐2.22
			Severe	and	
complicated	
	 11(9.17) 4(4.40) 0.18	 2.20	 0.68‐7.13
Clinical	outcomes	
Length	of	stay	(days)	 	 9.47(8.86) 8.2(7.81) 0.14	 1.02	 0.98‐1.05
ICU	stay	 1	 39(32.77) 25(27.47) 0.41	 1.29	 0.71‐2.34
Total	Cost		(Dollars)	 2	 63,381(84,024) 52,307(60,508) 0.19	 	
Received	CDI	
Treatment	
	 111(92.50) 82(90.11) 0.54	 1.35	 0.52‐3.56
			Metronidazole	 	 56(46.67) 43(47.25) 0.93	 0.98	 0.56‐1.69








	 13(10.83) 13(14.29) 0.45	 0.73	 0.32‐1.66
				Death‐associated	to	
CDI	*	













































































Antibiotic	history		 2.74 0.24 0.28	 0.22
H2	Receptor	Blocker	use		 1.69 0.50 	
Proton	Pump	Inhibitor	use	 1.88 0.40 1.35	 0.71
Corticosteroid	use		 1.64 0.51 	
Chemotherapy	 0.16 0.004 0.12	 0.21
Previous	hospitalization	 8.12 0.73 5.47	 0.06
Previous	surgery		 0.75 0.73 	
Previous	CDI	episode	 2.58 0.37 0.63	 0.70
Laxatives	(previous	week)	 1.37 0.68 	
Enteral	tube	 5.82 0.24 4.10	 0.36
Severity	and	clinical	outcomes
WBC	(thou/mcL)	 1.05 0.45 	
Creatinine	(mg/dL)	 1.11 0.52 	
30‐days	Mortality	risk		 0.60 0.12 	
Charlson	Comorbidity	Score	 2.22 0.01 1.91	 0.05
CDI	severity		 	
			Mild	 0.61 0.56 	
			Moderate	 0.62 0.55 	
			Severe	 1.65 0.52 	
			Severe	and	complicated	 5.09 0.33 2.55	 0.61



































































































































































































































































































































































































































































































































































































































































			002	 40,295 0.002665654 (7,	30)
			106	 184,555 0.012208954  (7,	30)


















0% 0% 0%	 0%	
Alternate	regimen:	pulses	every	
72hr	for	2	weeks	
0% 0% 0%	 0%	
Alternate	regimen:	with	only	1	week	
of	125	mg/L	four	times	a	day		
0% 0% 0%	 0%	




0.6% 0.2% 0%	 0%	
SHEA/IDSA:		without	initial	regular	
txt	+	48hr	pulses	for	2	weeks	
0% 0.2% 0%	 0%	
SHEA/IDSA:	without	initial	regular	
txt	+	72hr	pulses	for	4	weeks	
0% 0% 0%	 0%	
SHEA/IDSA:	without	initial	regular	
txt	+	48hr	pulses	for	4	weeks	




0% 0% 0%	 0%	
ACG:	125mg/L	twice	a	day+10	
pulsed	doses		
0% 0.2% 0%	 0%	
ACG:	125	mg/L	4	times	a	day	+	only	
7	pulsed	doses	














































	 	 10	days		 	 	 	 	 	 	 	 	14	days	 	 	
C.		Ribotype	002	(1.2‐6.8%	recurrence)		 	 					 	 	 	
					 	
D.		Ribotype	014‐020	(0‐1.0%	recurrence)		
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Figure	5.12.		Simulated	recurrence	rate	by	ribotype:	differences	on	sporualation	rates	and	fraction	of	viable	spores	per	ribotype	are	
reflected	on	differences	on	recurrence	rates.	On	day	13	post	infection,	we	added	to	the	model	the	regular	vancomycin	CDI	treatment	
:125mg/L	four	times	a	day	for	10	days	(left)	or	125mg/L	four	times	a	day	for	14	days	(right).		The	black	solid	lines	represent	each	of	the	
500	runs	of	the	stochastic	model,	and	the	white	slashed‐line	represents	the	results	of		our	deterministic	model.	
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CHAPTER	VI	
Conclusions		
	
Clostridium	difficile	is	indeed	a	difficult	organism.		Although	the	last	
decades	have	increased	understanding	of	its	biology,	pathogenicity,	and	
transmission,	C.	difficile	remains	one	of	the	most	reported	causes	of	nosocomial	
infection	in	the	United	States	and	around	the	world.		Furthermore,	C.	difficile	
infection	(CDI)	has	spread	to	community	settings	and	now	infects	individuals	
previously	considered	low‐risk.		
This	dissertation	provides	new	insights	into	the	pathogenicity	and	
transmission	patterns	of	C.	difficile	within	its	human	host.	Although	much	
research	has	been	done	on	CDI,	much	of	the	research	has	used	animal	or	gut	
models.		Research	using	clinical	samples	directly	without	the	intermediate	‘in	
vitro’	component	to	approximate	the	sporulation	and	toxin	production	of	C.	
difficile	isolates	is	less	common.		The	primary	goal	of	this	dissertation	was	to	
provide	in	vivo	CDI	insights	and	to	apply	them	to	three	specific	areas:	1)	infection	
control	and	prevention,	2)	diagnosis,	and	3)	treatment.				
	 The	main	goal	of	our	first	study	was	to	characterize	the	in	vivo	association	
of	C.	difficile	spore	and	toxin	production	and	their	association	with	the	presence	
of	Candida	albicans.		We	observed	a	strong	positive	association	between	C.	
difficile	toxin	and	spore	levels,	with	the	association	varying	slightly	by	ribotype.		
Consistent	with	this	finding,	toxin	negative/PCR	positive	stool	samples	had	
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significantly	fewer	spores	than	toxin	positive	CDI	ones.		However,	contrary	to	our	
hypothesis,	the	presence	of	C.	albicans	did	not	modify	these	associations	in	our	
study	population.		Nevertheless,	ribotypes	027	and	078	were	significantly	
associated	with	high	levels	of	toxin	and	spores	and	C.	albicans	overgrowth	in	the	
gut.			
The	absence	of	a	C.	difficile	spore‐toxin	trade	off	within	its	human	host	
suggests	that	spore	production	may	enhance	pathogenicity	as	well	as	
transmission.		This	conclusion	has	important	implications	for	CDI	infection	
control	and	prevention.		A	spore‐toxin	association	implies	that	more	severe	
cases,	which	are	expected‐‐although	this	is	still	controversial‐‐	to	have	larger	
amounts	of	toxin,	will	also	be	shedding	larger	amounts	of	spores.		This	highlights	
the	importance	of	timely	CDI	patient	isolation.		Additionally,	it	suggests	that	extra	
precautions	should	be	taken	when	dealing	with	CDI	patients	in	the	ICU	or	other	
high‐risk	settings.		
Our	second	study	aimed	to	better	understand	the	clinical	and	
epidemiological	differences	between	CDI	patients	according	to	their	laboratory	
diagnosis.		We	investigated	if	the	differences	that	previous	authors	had	reported	
were	maintained	among	a	population	with	high	CDI	treatment	rates.	Like	
previous	investigators,	we	observed	that	toxin	negative	PCR	positive	patients	
had	a	less	severe	CDI	presentation	than	toxin	positive	patients.		In	addition,	we	
identified	a	strong	association	between	white	race	and	a	toxin	positive	CDI	
diagnosis,	which	was	maintained	even	after	controlling	for	known	CDI	risk	
factors.		Providing	further	evidence	to	support	these	differences	by	CDI	
laboratory	diagnosis	confirms	the	need	to	revise	and	standardize	the	current	
laboratory	algorithms	in	the	US.			
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	 In	this	same	study,	we	also	sought	to	identify	host‐risk	factors	associated	
with	fecal	spore	levels.		Spore	levels	were	strongly	associated	with	CDI	severity	
and	known	CDI	risk	factors	such	as	previous	history	of	antibiotics,	proton	pump	
inhibitors,	and	previous	hospitalization.		These	results	support	the	conclusions	
from	our	first	study,	that	the	more	severe	CDI	presentation,	the	more	spores	are	
shed.		Healthcare	workers	should	be	aware	that	these	patients	are	more	
infectious	and	that	already	established	precautions	should	be	followed	strictly	
and	even	heightened	when	dealing	with	patients	with	severe	CDI.			
In	our	third	study,	we	aimed	to	develop	an	in‐host	mathematical	model	to	
simulate	the	in	vivo	toxin	and	spore	levels	within	its	human	host.		We	created	
both	a	deterministic	and	stochastic	version	of	a	compartmental	model	to	
determine	the	role	of	sporulation	and	germination	patterns	in	recurrence	and	
the	effectiveness	of	current	tapered/pulsed	vancomycin	regimens	by	ribotype.		
All	of	the	evaluated	treatment	regimens	for	repeated	CDI	were	effective	in	
reducing	risk	of	an	additional	recurrence,	with	the	effectiveness	varying	by	
ribotype,	and	thus	by	their	sporulation	and	germination	patterns.		Furthermore,	
treatment	effectiveness	was	maintained	even	when	the	duration	or	dosage	of	
most	of	the	assessed	regimens	was	reduced.		These	results	highlight	that	
tapered/pulsed	vancomycin	regimens	might	be	further	modified	to	a	level	that	
better	protects	gut	microbiota	while	preventing	CDI	recurrence.		
These	results	suggest	several	lines	for	future	research.		Future	laboratory	
studies	should	elucidate	how	spore	and	toxin	production	are	linked	in	C.	difficile	
and	identify	bacterial	and	host	signals	regulating	their	productions	in	vivo.		
Clinical	studies	are	needed	to	improve	our	understanding	of	the	role	played	by	
asymptomatic	carriers	in	healthcare	and	community	settings.		Prospective	
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longitudinal	studies	are	warranted	to	clarify	the	significance	of	asymptomatic	
carriers	in	CDI	transmission.		Our	in‐host	mathematical	model	could	be	modified	
to	further	elucidate	the	role	of	asymptomatic	carriers.		In	addition,	more	
investigation	is	necessary	to	identify	if	there	is	a	racial/genetic	predisposition	to	
CDI	or	if	race	is	acting	as	a	proxy	of	a	group	of	other	independents	CDI	
predictors.		A	larger,	more	representative	study	that	incorporates	racial	groups	
other	than	whites	and	blacks,	and	includes	further	data	such	as	ethnicity	and	
nativity,	will	be	required.			Furthermore,	a	cost‐effectiveness	analysis	of	the	use	
of	molecular	tests	as	part	of	the	CDI	laboratory	diagnosis	should	be	performed.		
This	study	is	essential	for	estimating	the	economic,	social,	and	clinical	impact	of	
including	PCR	as	part	of	the	diagnosis.			Finally,	further	controlled	clinical	trials	
are	necessary	to	improve	CDI	treatment	regimens	to	minimize	CDI	recurrence	
and	to	lessen	gut	microbiota	disturbance.			
	 Collectively	this	dissertation	demonstrates	the	importance	of	considering	
the	pathogen	and	the	human	host	together	when	researching	CDI.		In	our	first	
study,	we	demonstrated	that	the	toxin‐spore	correlation	in	vivo	is	different	than	
the	one	previously	observed	in	vitro.		Similarly,	in	our	second	study,	we	identified	
the	importance	of	the	patient’s	clinical	presentation	when	receiving	a	toxin	
negative	PCR	positive	result.		Finally,	in	our	third	study	we	demonstrated	the	
importance	of	C.	difficile	sporulation	and	germination	patterns	for	CDI	recurrence	
and	thus,	for	the	effectiveness	of	CDI	treatment.		Thinking	of	CDI	as	a	
multifactorial	disease	promises	to	be	an	effective	path	towards	managing,	and	
controlling	and	preventing	CDI.	
	
